59.40
3.29 (5.86%)
| Previous Close | 56.11 |
| Open | 56.04 |
| Volume | 2,733,198 |
| Avg. Volume (3M) | 2,411,898 |
| Market Cap | 10,993,514,496 |
| Price / Earnings (Forward) | 2.50 |
| Price / Sales | 3.91 |
| Price / Book | 3.32 |
| 52 Weeks Range | |
| Earnings Date | 19 Feb 2025 - 24 Feb 2025 |
| Profit Margin | -7.95% |
| Operating Margin (TTM) | -2.61% |
| Diluted EPS (TTM) | -1.16 |
| Quarterly Revenue Growth (YOY) | 12.80% |
| Total Debt/Equity (MRQ) | 86.62% |
| Current Ratio (MRQ) | 2.12 |
| Operating Cash Flow (TTM) | 233.02 M |
| Levered Free Cash Flow (TTM) | 97.26 M |
| Return on Assets (TTM) | -2.16% |
| Return on Equity (TTM) | -6.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Exact Sciences Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.13 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 1.01% |
| % Held by Institutions | 101.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Bernstein, 51.52%) | Buy |
| Median | 73.50 (23.74%) | |
| Low | 60.00 (Evercore ISI Group, 1.01%) | Buy |
| Average | 73.00 (22.90%) | |
| Total | 14 Buy | |
| Avg. Price @ Call | 56.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 13 Dec 2024 | 72.00 (21.21%) | Buy | 61.25 |
| BTIG | 26 Nov 2024 | 75.00 (26.26%) | Buy | 60.10 |
| 06 Nov 2024 | 65.00 (9.43%) | Buy | 54.72 | |
| TD Cowen | 26 Nov 2024 | 86.00 (44.78%) | Buy | 60.10 |
| 06 Nov 2024 | 82.00 (38.05%) | Buy | 54.72 | |
| Piper Sandler | 11 Nov 2024 | 75.00 (26.26%) | Buy | 51.33 |
| Baird | 06 Nov 2024 | 67.00 (12.79%) | Buy | 54.72 |
| Benchmark | 06 Nov 2024 | 65.00 (9.43%) | Buy | 54.72 |
| Canaccord Genuity | 06 Nov 2024 | 75.00 (26.26%) | Buy | 54.72 |
| 29 Oct 2024 | 95.00 (59.93%) | Buy | 69.64 | |
| Citigroup | 06 Nov 2024 | 75.00 (26.26%) | Buy | 54.72 |
| Craig-Hallum | 06 Nov 2024 | 65.00 (9.43%) | Buy | 54.72 |
| Evercore ISI Group | 06 Nov 2024 | 60.00 (1.01%) | Buy | 54.72 |
| 01 Oct 2024 | 80.00 (34.68%) | Buy | 68.04 | |
| Goldman Sachs | 06 Nov 2024 | 65.00 (9.43%) | Buy | 54.72 |
| Jefferies | 06 Nov 2024 | 85.00 (43.10%) | Buy | 54.72 |
| Stifel | 06 Nov 2024 | 67.00 (12.79%) | Buy | 54.72 |
| Bernstein | 30 Oct 2024 | 90.00 (51.52%) | Buy | 70.46 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Nov 2024 | Announcement | Exact Sciences to Participate in December Investor Conferences |
| 25 Nov 2024 | Announcement | Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024 |
| 13 Nov 2024 | Announcement | Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy |
| 05 Nov 2024 | Announcement | Exact Sciences Announces Third-Quarter 2024 Results |
| 01 Nov 2024 | Announcement | Exact Sciences to Participate in November Investor Conference |
| 27 Oct 2024 | Announcement | Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement |
| 08 Oct 2024 | Announcement | Exact Sciences Schedules Third Quarter 2024 Earnings Call |
| 04 Oct 2024 | Announcement | FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |